A team of researchers from Birmingham, led by the Pr. Stankovic has published results on the death of CLL cells human induced inhibition of USP7 in vitro and in vivo
Download the free guide
Boost your gains
The HBX 19,818, an inhibitor of USP7 patented by Hybrigenics, kills CLL cells in vitro human and in vivo
The HBX 19,818 exerts a synergy with the chemotherapeutic agents, alkylating DNA, such as cyclophosphamide
The HBX 19,818 kills CLL cells human chemo-resistant in vitro and in vivo
Paris, may 18, 2017 Hybrigenics (ALHYG), a biopharmaceutical group listed in Paris on the Alternext market of Euronext, eligible for the PEA-PME, focused in the research and development of new drugs against cancer, announced today the publication of a scientific article in the prestigious journal “Blood” of the American Society of Hematology ” by a team of researchers from Birmingham, uk, led by Professor T. Stankovic. This article describes the cytotoxic activity induced by the inhibition of the “Ubiquitin-Specific Protease 7” (USP7) on the cells of Chronic Lymphocytic Leukemia (CLL) in vitro human and in vivo.
“This study validates the importance of the Ubiquitin-Specific Protease 7 (USP7) as a novel potential therapeutic target for the treatment of Chronic Lymphocytic Leukemia. Hybrigenics is the owner of two series of patented small molecules inhibiting specifically USP7, one reversible and the other irreversible, which belongs to the HBX 19,818. The HBX 19,818 is the first inhibitor of USP7 to reveal a potential to kill Chronic Lymphocytic Leukemia cells in vitro as well as in preclinical models in vivo in mice, alone or in synergy with cyclophosphamide, an essential component of the immuno-chemotherapy of reference for the treatment of Chronic Lymphocytic Leukemia. In addition, the HBX 19,818 showed the same activity as active principle, single-cell Chronic Lymphocytic Leukemia chemo-resistant, “says Rémi Delansorne, ceo of Hybrigenics, who adds :” These results, published in the prestigious scientific journal Blood, represent a demonstration preclinical very encouraging for a potential therapeutic. The procedure for Hybrigenics is now to choose our best series and optimize chemically before being able to select a candidate anticancer drug to be developed. ”
The summary of the publication can be accessed on-line : www.ncbi.nlm.nih.gov/pubmed/28495793
Download the free guide
Boost your gains
